Bayesian probability of success for clinical trials using historical data

Developing sophisticated statistical methods for go/no-go decisions is crucial for clinical trials, as planning phase III or phase IV trials is costly and time consuming. In this paper, we develop a novel Bayesian methodology for determining the probability of success of a treatment regimen on the basis of the current data of a given trial. We introduce a new criterion for calculating the probability of success that allows for inclusion of covariates as well as allowing for historical data based on the treatment regimen, and patient characteristics. A new class of prior distributions and covariate distributions is developed to achieve this goal. The methodology is quite general and can be used with univariate or multivariate continuous or discrete data, and it generalizes Chuang-Stein's work. This methodology will be invaluable for informing the scientist on the likelihood of success of the compound, while including the information of covariates for patient characteristics in the trial population for planning future pre-market or post-market trials.

[1]  Joseph G Ibrahim,et al.  Bayesian Design of Noninferiority Trials for Medical Devices Using Historical Data , 2011, Biometrics.

[2]  Rajeshwari Sundaram,et al.  Flexible Bayesian Human Fecundity Models. , 2012, Bayesian analysis.

[3]  Ivan S F Chan,et al.  Safety and Immunogenicity Profile of the Concomitant Administration of ZOSTAVAX and Inactivated Influenza Vaccine in Adults Aged 50 and Older , 2007, Journal of the American Geriatrics Society.

[4]  P. McCullagh.  Regression Models for Ordinal Data , 1980 .

[5]  Nigel Stallard,et al.  Decision‐making in a phase II clinical trial: a new approach combining Bayesian and frequentist concepts , 2005 .

[6]  Fei Wang,et al.  A simulation-based approach to Bayesian sample size determination for performance under a given model and for separating models , 2002 .

[7]  R G Hill,et al.  Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.

[8]  Joseph G. Ibrahim,et al.  A conditional model for incomplete covariates in parametric regression models , 1996 .

[9]  Haoda Fu,et al.  Evaluating and utilizing probability of study success in clinical development , 2013, Clinical trials.

[10]  David J. Spiegelhalter,et al.  Bayesian Approaches to Randomized Trials , 1994, Bayesian Biostatistics.

[11]  J. Ibrahim,et al.  Power prior distributions for regression models , 2000 .

[12]  Christy Chuang-Stein,et al.  Sample size and the probability of a successful trial , 2006, Pharmaceutical statistics.

[13]  Ivan S. F. Chan,et al.  A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of Zostavax , 2007, Clinical and Vaccine Immunology.

[14]  Joseph G. Ibrahim,et al.  Missing covariates in generalized linear models when the missing data mechanism is non‐ignorable , 1999 .

[15]  Anthony O'Hagan,et al.  Assurance in clinical trial design , 2005 .

[16]  J G Ibrahim,et al.  Maximum Likelihood Methods for Cure Rate Models with Missing Covariates , 2001, Biometrics.

[17]  W. Gilks,et al.  Adaptive Rejection Sampling for Gibbs Sampling , 1992 .

[18]  Jarmo Hietala,et al.  Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder , 2006, Biological Psychiatry.

[19]  Ming-Dauh Wang,et al.  Bayesian predictive approach to interim monitoring in clinical trials , 2006, Statistics in medicine.

[20]  Yiyi Chen,et al.  A new statistical decision rule for single-arm phase II oncology trials , 2016, Statistical methods in medical research.

[21]  S. Fienberg,et al.  Identification and estimation of age-period-cohort models in the analysis of discrete archival data , 1979 .